Dr. Ginsburg Discusses the Use of VIA in Cervical Cancer Screening

Video

In Partnership With:

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses the use of visual inspection with acidic acid (VIA) in cervical cancer screening.

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses the use of visual inspection with acidic acid (VIA) in cervical cancer screening.

Although VIA is a well-known practice, Ginsburg says that in the last few years, WHO recommended it after a large project in sub-Saharan African countries showed that it was effective, acceptable, and feasible to implement by non-gynecologists and even non-physicians, such as nurses and midwifes. Ginsburg says that there are certain criteria by which health workers are trained to identify those women who have those changes and are also suitable for treatment, even during the same visit, with cryotherapy.

VIA is one of 3 strategies that WHO recommends, along with HPV DNA testing and Pap testing. This approach is considered a cost-effective intervention in global health that can be implemented in a rural setting where no physicians are available, Ginsburg says.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD